In this multicentric random double-blind study versus placebo, the therapeutic activity of timed-release dihydroergotamine preparation 10 mg/per os/day has been tested in 90 patients affected by common migraine. The drug presented a prophylactic effect on recurrent headache, mainly on night and awakening migraine. A low incidence of side-effects with no weight changes or other effects on physiologic events was registered.
Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation / N. Martucci;V. Manna;P. Mattesi;G. Troiani;G. C. Manzoni;M. Lanfranchi;G. Bono;G. Micieli. - In: CEPHALALGIA. - ISSN 0333-1024. - 3 Suppl 1(1983), pp. 151-155.
|Tipologia ministeriale:||Articolo su rivista|
|Appare nelle tipologie:||1.1 Articolo su rivista|